Fleroxacin is a new broad-spectrum quinolone which can be given by the oral route. The present study was designed to assess the influence of bacteremia on the pharmacokinetics of a single oral dose of fleroxacin. Thirteen patients with proven bacteremia (one or more pairs of positive blood cultures, no hypotension) were given a single 400-mg fleroxacin dose orally on two occasions while also receiving standard antibiotic therapy.
significantly, reduced during the bacteremic phase (oral clearance, 43.8 + 23.5 versus 48.5 + 17.5 ml/min).
When compared with previous results obtained in healthy young subjects, longer times to the maximum concentration of drug in serum and elimination half-lives and higher areas under the curve were observed. This could be due to the bacteremic state, the old age of the patients (mean, 66 years), and the low renal clearance (mean calculated creatinine clearance, 71.1 ml/min). A single oral dose of 400 mg of fleroxacin provides sufficient levels in serum to cover susceptible microorganisms for at least 24 h in bacteremic patients. Renal function appeared to be the key element that had to be taken into consideration to adapt fleroxacin dosage profiles in our patient population. Bacteremia itself appeared to amplify that phenomenon, but to a much lesser extent than renal function did.
Fleroxacin is a new trifluorinated quinolone that differs from most other quinolones by its excellent bioavailability (reaching almost 100%) and a longer terminal half-life (t112,; 10 h) following oral administration (53, 54) . It is eliminated primarily by renal clearance, with about 60 to 70% of a dose being recovered unchanged in the urine within 96 h (53) (54) (55) . These pharmacokinetic properties associated with a wide antibacterial spectrum (5, 7, 24, 35, 37, 55, 56) and a high degree of penetration into body fluids and tissues (12, 26, 27, 36, 44, 52) allow a once-a-day oral administration. The pharmacokinetic parameters of fleroxacin in healthy young volunteers are well known (33, 44, 53, 54) . However, serious infections may lead to changes in these parameters through various mechanisms (1, 2, 4, 6, 13, 28, 49, 50) . Moreover, severely ill patients are mostly elderly people who often suffer from other underlying diseases. Volunteers can be tested after an overnight fast, whereas patients must be treated at any time, whether they are fasting or not. Volunteers are administered only the drugs to be tested, whereas hospitalized patients typically need other drugs.
All of these factors, as well as the decreased renal function which is frequently observed in patients with severe infections, can influence the absorption and dispositions of drugs. Furthermore, the pharmacokinetics of orally administered antibiotics can change in the same patient as the disease goes from the acute phase to the convalescence phase. The pharmacokinetics of single oral doses of fleroxacin were therefore investigated in patients during bacteremia (acute disease phase) and about 1 week later (convalescent phase).
MATERIALS AND METHODS
Patients. Patients over 18 years of age hospitalized at the University Hospital of Geneva, Geneva, Switzerland, were considered for inclusion in the study, provided that they were able to give written informed consent and were able to take medication by mouth, did not have hypotension, and had at least one positive blood culture showing the same pathogen in both of a pair of bottles. To be included in the study, cultures had to be reported as positive by the microbiological laboratory within 24 h after the blood was drawn.
ANTIMICROB. AGENTS CHEMOTHER.
In addition to fleroxacin, all patients received standard antibiotic therapy with penicillins, aminoglycosides, or cephalosporins. The choice and duration of that antibiotic therapy were determined by the physician responsible for the patient exclusively on the basis of clinical considerations. Other orally administered medications were not to be given 1 h (2 h for antacids) prior to or following the administration of fleroxacin.
A medical history, a physical examination, and a panel of laboratory tests (renal and liver chemistries, complete blood cell counts) were obtained on days 1 and 7 of the study. Renal creatinine clearances were calculated as described by Cockcroft and Gault (14) . The protocol was approved by the Geneva University Hospital's ethical review board.
Study design. The study described here was an open-label, nonrandomized, within-subject comparative pharmacokinetic trial. Patients consenting to be studied received one 400-mg tablet of fleroxacin orally no later than 36 h after the last positive blood culture was drawn (day 1). No special diet was required for the patients in the study. Blood samples of 5 ml were collected by using sodium fluoride and potassium oxalate as anticoagulants before fleroxacin intake and at 1, 2, 4, 12, 24, and 48 h after fleroxacin intake. Identical drug administration and sampling schedules were repeated 7 ± 2 days later, at a time when the patient's condition had stabilized.
After centrifugation (1,000 x g for 15 min), plasma samples were transferred to polyethylene-stoppered glass tubes covered with aluminum foil to prevent photodegradation and were then stored at -20°C until they were assayed.
Microbiological investigations. Blood cultures were performed by using Roche Septi-Check and Oxoid Signal (F. Hoffmann-La Roche, Basel, Switzerland) bottles as a paired blood culture system; each bottle was inoculated with 10 ml of blood.
Fleroxacin assay. The concentrations of fleroxacin in plasma were determined by a reversed phase high-pressure liquid chromatography technique described by Dell et al. (15) and Heizmann et al. (22) . The mobile phase was 5 mM tetrabutylammonium hydrogen sulfate-methanol (72/28; vol/vol), and separation was performed on a Toyo Soda ODS-120 T 5-,um column. Concentrations of fleroxacin in plasma were detected fluorimetrically (excitation at 290 nm; emission at 450 nm); the limit of quantification was 20 ng/ml (relative standard deviation, 3.6%).when 0.5-ml plasma samples were used. The mean interassay reproducibility was 4% relative standard deviation over the concentration range of 0.02 to 5 ,ug/ml. Recovery from plasma was 81% (relative standard deviation, 10%) over the concentration range 0.01 to 5 ,ug/ml. The coefficient of variation of multiple determinations was less than 15%.
Pharmacokinetic analysis. The software used for the fitting procedure was EXCEL 4.0 (Microsoft). Standard algorithms for nonlinear curve-fitting were implemented, and objective function was minimized with the solver module included in the EXCEL 4.0 package. Visual inspection of the log-linearized data showed a monophasic decline in the fleroxacin concentration in the plasma of all subjects and no absorption delay. Monophasic elimination with first-order absorption was therefore assumed, and a biexponential model without a lag time was fitted to the untransformed data, with weighting proportional to the inverse of the predicted values. The maximum concentration of drug in plasma (Cm.) Table 2 . There were no significant changes in the following mean ± standard deviation pharmacokinetic parameters: Cm., 6.4 ± 1.5 versus 6.7 ± 1.9 mg/liter; Cmin, 3.0 ± 1.7 versus 2.5 ± 1.2 mg/liter; Tmax, 2.3 + 1.4 versus 2.0 ± 1.2 h; and tl/2, 19.7 ± 8.0 versus 17.9 ± 6.9 h. Individual fleroxacin levels in serum 24 h after administration of the dose (Cmin) were all greater than 1 mg/liter on day 1 and day 7 ± 2. Tmaxs exhibited wide interindividual variabilities, but they seemed to be characteristic for each individual. Oral clearance was only slightly (10.8%), but not significantly (P = 0.15), reduced during the bacteremic (acute) phase compared with that during the convalescent phase. Individual fleroxacin clearances measured on days 1 and 7 were highly correlated for each individual patient (R2 = 0.787; P = 0.001). Drug clearances appeared to be related to creatinine clearances on day 1 (P < 0.001). However, this correlation was no longer statistically significant when the data obtained on day 7 were considered ( Fig. 2) . There was a trend (P = 0.06) toward a positive correlation between the age of the patients and the oral clearance of fleroxacin (Fig. 3) . DISCUSSION The broad spectra of activity and the bactericidal nature of the fluoroquinolones, together with their high levels of absorption, rapid distributions, and elevated concentrations in tissues, (11, 20, 28) , which may increase -ral recent studies and reviews have dealt with the effects metabolic clearance, seem to be counterbalanced by an inhibition of liver enzyme activity (19 [53] [54] [55] and suggest that the kinetics of absorption are not modified. However, TmnXs varied from 0.9 to 5.4 h in our patients, whereas they varied from 0.5 to 3.0 h in healthy young volunteers. Analysis of Tmax strongly suggests a role for the characteristics of the individual patient in that broad distribution. Modifications of drug distribution are possible in the bacteremic (acute) phase of disease or in older people (48) . However, this point was not assessed in our study since changes in the apparent volume of distribution cannot be independently estimated after oral administration.
A correlation (R2 = 0.787) between fleroxacin clearances was observed on day 1 and day 7 in the same individuals. There was a 10% increase in fleroxacin clearance between the bacteremic (acute) phase and the convalescent phase which did not reach statistical significance or, probably, clinical relevance. Although fleroxacin clearance increased slightly between the acute phase of the disease and the convalescent phase, it was still much lower on day 7 in our patients than in healthy young volunteers (Table 2) .
In marked contrast to the results of the present study in a previous study (16) performed under identical conditions after administration of a single oral dose of ciprofloxacin, peak concentrations varied by a factor of 14.5 and no correlation in the AUCO_24h could be found in bacteremic patients between day 1 and day 5. A positive correlation was found in the same study (16) when ciprofloxacin was administered as a single intravenous dose, suggesting erratic absorption of ciprofloxacin during bacteremia. The pharmacokinetics of orally administered fleroxacin therefore appear to be more predictable than those of orally administered ciprofloxacin during bacteremia, possibly because of a more reliable absorption of fleroxacin (16) .
Comparisons between different studies are hazardous because the experimental designs of and methods used in different studies are never strictly comparable. However, while care should be taken not to overinterpret the data in Table 2 , it could well be that the extended t1/2, and lower clearance are of clinical importance. One striking difference is the important decrease in the clearance in our elderly patients compared with the clearance in healthy young volunteers (Table 2) . Fleroxacin clearance on day 1 was clearly correlated to the estimated creatinine clearance (Fig. 2) . This point is not surprising, since fleroxacin is eliminated mostly by the renal route (approximately 60 to 70%) (53) (54) (55) (29) . The correlation between fleroxacin clearance and creatinine clearance (Fig. 2) (10, 31) . Quinolones mainly eliminated by the kidneys, such as ofloxacin or fleroxacin, behave differently and are more dependent on the possible coexisting renal dysfunction (31) . These considerations about quinolones and their metabolism have recently been reviewed (33, 43) .
The slightly reduced oral clearance and prolonged tl2, of fleroxacin in our bacteremic patients led to a trend toward higher CminS on day 1 than on day 7. On day 1, all patients had Cmins greater than 1 mg/ml, and more than half of them had Cmins greater than 2 mg/ml. These values are greater than the MICs for 90% of the most common pathogens that are susceptible to fleroxacin (37) .
In conclusion, the pharmacokinetic effects observed in the present study appeared to be related mainly to the decrease in renal clearance typical of elderly patients. Bacteremia itself appears to amplify that phenomenon, but to a much lesser extent than age does. Fleroxacin dosage in bacteremic patients does not require any specific consideration. Adaptation of the fleroxacin dosage according to the usual procedure in patients with reduced renal function is recommended, however, whenever creatinine clearance is significantly lower (<40 ml/min) (23, 48, 51) , with administration of a normal 400-mg loading dose followed by 200-mg maintenance doses (51) .
